Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]
Gynecol Oncol Rep
.
2021 Mar 1:36:100740.
doi: 10.1016/j.gore.2021.100740.
eCollection 2021 May.
Authors
Jonathan Oh
1
,
Minal Barve
1
2
,
Neil Senzer
3
,
Phylicia Aaron
3
,
Luisa Manning
3
,
Gladice Wallraven
3
,
Ernest Bognar
3
,
Laura Stanbery
3
,
Staci Horvath
3
,
Meghan Manley
3
,
John Nemunaitis
3
,
Adam Walter
4
,
Rodney P Rocconi
5
Affiliations
1
Texas Oncology, P.A., Dallas, TX, United States.
2
Mary Crowley Cancer Research Centers, Dallas, TX, United States.
3
Gradalis, Inc., Carrolton, TX, United States.
4
ProMedica, Toledo, OH, United States.
5
University of South Alabama - Mitchell Cancer Institute, Mobile, AL, United States.
PMID:
34095420
PMCID:
PMC8169695
DOI:
10.1016/j.gore.2021.100740
Abstract
[This corrects the article DOI: 10.1016/j.gore.2020.100648.].
© 2021 The Author(s).
Publication types
Published Erratum